Webinar: Rapid single cell functional characterization for cell therapy potency
Webinar: Rapid single cell functional characterization for cell therapy potency
See how VivaCyte immune cell potency measurement is guiding selection and predictive screening
In this webinar DKFZ Heidelberg’s DNA vector expert Dr Richard Harbottle and Cellply’s co-founder Dr Massimo Bocchi will introduce the VivaCyte characterization platform and discuss how Dr Harbottle’s team is using VivaCyte to accelerate their work on the measurement and optimization of potency and fitness of novel TCR-T cell therapies.
Duration: 30 mins
Discover:
- VivaCyte and explore how this next generation single-cell functional analysis platform provides actionable insights that are streamlining cell therapy discovery and development.
- The novel microfluidics and ability to repeatedly exchange media around the cells during an assay that allows VivaCyte to provide true flexibility of in-depth single-cell level characterization of your immune cell candidate.
- Understand how you can investigate and rapidly characterize every cell for both function and phenotype to assess potency, fitness, and the impact of production processes.
PRESENTERS
As a novel therapeutic modality, cell-based therapy is revolutionizing the pharmaceutical industry. As this nascent field of more effective, often curative, living cells rapidly evolves its goal is clear – to deliver therapies that induce a targeted and persistent killing effect.
Increasing understanding of the complexity that underlies these heterogenous therapies, and the impact on potency and persistence, is critical as the industry strives to better define and control these vital therapies, while decreasing their overall cost.
Application of this modality is rapidly broadening beyond the initial hematological cancer focus and moving to address solid tumors and inflammatory diseases. The pressure is on to deliver analytical characterization tools that increase the depth, breadth, and robustness of measurement currently available across R&D and into manufacturing.